JNJ Johnson & Johnson

Johnson & Johnson is a global healthcare conglomerate with major positions in pharmaceuticals and MedTech devices, following the spin-off of its consumer health unit. Sector: Healthcare.

Johnson & Johnson (JNJ) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

On the question of capital productivity, ROIC is 13.84%, WACC is 5.92%, and the economic spread is 7.92%. On balance, returns on capital just exceed funding costs, implying limited but real value creation at the margin. Supporting metrics show ROE at 34.74% and ROA at 11.32%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that is value-creative but with less room for execution slippage.

From a market pricing perspective, trailing P/E of 22.01, forward P/E of 21.06, PEG of 2.62. With trailing and forward P/E closely aligned, the market appears to be pricing the company on the assumption that earnings remain broadly stable near term. On a growth-adjusted basis, the company carries a premium valuation relative to its growth rate. The company carries an aggregate current ratio of 1.03, pointing to constrained near-term balance sheet coverage. The overall valuation picture is one where the market is paying for a specific earnings and growth outcome — and where any deviation from that path would likely pressure multiples.

The margin stack reads as follows: gross margin sits at 67.98%, operating margin at 27.56%, and free cash flow margin at 20.65%. Gross margins at this level typically indicate businesses with structural pricing advantages and low direct cost sensitivity. The company's operating margins are solid, pointing to overhead management that appears to be a relative strength. FCF margins are constructive here, reflecting the company that generate cash reliably after reinvestment requirements. Viewed together, these readings indicate a company that converts revenue into both earnings and cash with discipline.

The forward view combines two signals: the estimated 12-month price change of 2.80%, where analyst estimates suggest only incremental upside absent a positive surprise, while TTM revenue growth of 10.90% suggesting the company is growing revenues at a measured, sustainable pace. Analyst estimates point to EPS growth of 4.5%, suggesting steady earnings progress that supports the current multiple on a forward basis. One metric reflects operational reality, the other market expectation — both are useful inputs, but neither should be read in isolation. The interaction between revenue execution and analyst repricing will ultimately determine how closely realized returns track current expectations. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

There is enough quality in the profile to avoid outright concern, but not enough uniform strength to take high conviction in a direction. Patience has merit here.

This assessment is based solely on the quantitative metrics presented above and does not constitute financial advice. Investors should consider their own risk tolerance and conduct independent research before making investment decisions.